Mol Biol Rep. 2025 Dec 12;53(1):192. doi: 10.1007/s11033-025-11350-0.
ABSTRACT
Diabetes mellitus (DM), the ninth leading cause of death worldwide, is characterized by a relative or absolute deficiency of insulin, leading to increased production of advanced glycosylation end-products (AGEs), which further enhances oxidative and nitrosative stress, often leading to a variety of macrovascular and microvascular complications, such as diabetic nephropathy (DN), retinopathy, and neuropathy. Especially, diabetic patients with end stage renal disease (ESRD) usually have concomitant severe peripheral arterial disease. Unfortunately, there is still no effective therapeutic treatment for DM patients combined with DN and diabetic foot ulcer (DFU). Thus, we performed a series of bioinformatics analyses to investigated the molecular mechanisms involved in the occurrence of these two complications. We screened for differentially expressed genes (DEGs) from the Gene Expression Omnibus (GEO) database, namely GSE96804 and GSE134431, and conducted enrichment and protein-protein interaction analyses. Subsequently, we constructed animal models of these two diseases in vivo, and validated the predictions' accuracy using quantitative real-time PCR (qPCR) experiments to confirm the expression levels of mRNA. Finally, we conducted protein-chemical interactions and drug prediction. We identified 104 DEGs, with many of them being involved in inflammation or lipid metabolism. We obtained 7 hub genes closely related to DN and DFU, and verified through animal experiments that the expression trends of 5 of them (NID2, LUM, ECM, LTBP1 and LRRC2) were consistent with the results of bioinformatics analysis. Notably, our study showed that sex hormones including pirinixic acid, testosterone enanthate, and progesterone were predicted to be the most promising drugs, with the combined score of the three being the highest. This finding may potentially provide common therapeutic targets for DN and DFU. Additionally, it is important to understand these networks and hub genes to advance our understanding of the multifaceted complications of DM and the future development of drugs to treat these complications.
PMID:41385029 | DOI:10.1007/s11033-025-11350-0